Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. (JUMP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01493414
Recruitment Status : Completed
First Posted : December 16, 2011
Results First Posted : April 26, 2019
Last Update Posted : April 26, 2019
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The primary objective of this study was to collect additional safety of INC424 in patients with Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis, who either received prior treatment with commercially available agents or who have never received treatment.

Condition or disease Intervention/treatment Phase
Myelofibrosis Drug: INC424 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2233 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF).
Study Start Date : August 16, 2011
Actual Primary Completion Date : January 26, 2017
Actual Study Completion Date : January 26, 2017


Arm Intervention/treatment
Experimental: INC424
5 - 25 mg twice a day (BID)
Drug: INC424
All patients enrolled into the study will receive INC424 (ruxolitinib). Starting dose is based on baseline platelet counts, with doses ranging from 5 to 20 mg twice a day. No INC424 dose will exceed 25 mg BID orally.
Other Name: Ruxolitinib




Primary Outcome Measures :
  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 5 Years [ Time Frame: Baseline up to approximately 5 years ]
    An adverse event (AE) is any untoward medical occurrence in a clinical trial participant regardless of causal relationship to study drug and regardless whether study drug has been administered. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A non-serious AE is any AE that does not meet the criteria above.


Secondary Outcome Measures :
  1. Percentage of Participants With at Least 50% Reduction in Spleen Length [ Time Frame: Baseline up to approximately 5 years ]
    Spleen length was assessed by manual palpation. Assessment of spleen response was repeated until early discontinuation of the study drug and also at study completion (28 days post end of treatment visit).

  2. Number of Participants With Best Overall Response (BOR) up to 5 Years According to Spleen Length [ Time Frame: Baseline up to approximately 5 years ]

    Overall response is analyzed using the spleen response, as assessed by the investigator and also by deriving the response using International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria.

    Participants with spleen length at baseline between 5 and 10 cm were reported as Responders if reporting non palpable spleen; Stable disease does not meet criteria for response or disease progression and Progressive disease with an increase of 100% from baseline in spleen length.

    Participants with spleen length at baseline more than 10 cm were reported as Responders with spleen reduction of 50% from baseline; Stable disease does not meet criteria for response or disease progression and Progressive disease with an increase of 50% from baseline in spleen length.


  3. Change in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to Worst Post-baseline ECOG Status up to 5 Years [ Time Frame: Baseline up to approximately 5 years ]
    ECOG Performance Score has 5 grades. 0 = Fully active, able to carry out all pre-disease activities; 1 = Restricted in strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities. Active about 50% of waking hours; 3 = Capable of limited self-care, confined to bed/chair more than 50% of waking hours; 4 = Completely disabled; cannot carry on self-care. Totally confined to bed/chair. 5 = Death.

  4. Change in Functional Assessment of Cancer Therapy (FACT-TOI, FACT-G) and FACT-Lymphoma (FACT-Lym) Total Scores Measured at Baseline and Week 48 [ Time Frame: Baseline and Week 48 ]
    The FACT-Lym questionnaire consists of a total of 42 questions divided between five subscales (i.e., physical well-being, social/family well-being, emotional well-being, functional well-being and lymphoma subscale). Each subscale questionnaire rates each question on a 5-point scale from 0 = Not at all to 4 = Very much. These scores were summed to three total sum scores, namely FACT-Lym score, FACT-Lym Trial Outcome Index (TOI), FACT-General (FACT-G) and FACT-Lym total score. Total scores: FACT-Lym=0-60, FACT-TOI=0-116, FACT-G total=0-108, FACT-Lym Total= 0-168. Higher scores are reflective of better HRQoL.

  5. Time to First Improvement in FACT-Lym, FACIT-Fatigue Score and ECOG Performance Status [ Time Frame: Baseline up to approximately 5 years ]
    Improvement was defined by the upper limit of the minimally important difference (MID). Patients with the best possible score at Baseline were excluded from this analysis because their HRQoL cannot be further improved. Responders and non-responders for each endpoint were defined based on change from baseline scores using pre specified cut-off points. Patients with an improved score compared to Baseline, for which the magnitude of the change was at least the cutoff value, were classified as responders; otherwise, as non-responders. The responder cutoff: ECOG cutoff=1, range=0 to 5, FACT-Lym cutoff=5.4, range 0-60, FACIT-Fatigue =5 and range=0-52.The median time to first improvement was estimated using the Kaplan Meier method and time to improvement event was determined based on upper bound of the MID. The time to improvement was calculated from the date of first study drug administration.

  6. Medical Resource Utilization up to 5 Years [ Time Frame: Baseline up to approximately 5 years. ]
    Percentage of patients requiring medical resources (blood transfusions, hospitalization, emergency room visits, general practitioners or specialists consultations, urgent care or splenic irradiation) up to 5 years.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  1. Patients must not be eligible for another ongoing INC424 clinical trial.
  2. Patients must be diagnosed with PMF, PPV MF or PET-MF, according to the 2008 revised International Standard Criteria, irrespective of JAK2 mutation status..
  3. Patients with PMF requiring therapy must be classified as high risk (3 prognostic factors) OR intermediate risk level 2 (2 prognostic factors, no more), OR intermediate risk level 1 (1 prognostic factor, no more) with an enlarged spleen (assessment to occur at the Screening Visit).

    The prognostic factors, defined by the International Working Group are:

    • Age > 65 years;
    • Presence of constitutional symptoms (weight loss, fever, night sweats);
    • Marked anemia (Hgb < 10g/dL)*;
    • Leukocytosis (history of white blood cell (WBC) > 25 x109/L);
    • Circulating blasts > 1%. * A hemoglobin value < 10 g/dL must be demonstrated during the Screening Visit for patients who are not transfusion dependent. Patients receiving regular transfusions of packed red blood cells will be considered to have hemoglobin < 10 g/dL for the purpose of evaluation of risk factors.
  4. Patients with Intermediate-1 disease and splenomegaly must have a palpable spleen measuring 5 cm or greater from the costal margin to the point of greatest splenic protrusion.
  5. Patients must have a peripheral blood blast count of < 10%.
  6. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
  7. Fedratinib pretreated patients with documented complete physical examination including full neurologic examination and cardiology assessment, thiamine level testing, and MRI of the brain if indicated based on signs or symptoms. Patients pretreated with fedratinib should have completed or be receiving thiamine supplementation according to the investigator's instructions.

Main Exclusion Criteria:

  1. Patients eligible for hematopoietic stem cell transplantation (suitable candidate and a suitable donor is available).
  2. Patients with history of malignancy in past 3 years except for treated, early-stage squamous or basal cell carcinoma in situ.
  3. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral INC424 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection).
  4. Patients with cardiac disease which in the Investigator's opinion may jeopardize the safety of the patient or the compliance with the protocol.
  5. Patients with currently uncontrolled or unstable angina, rapid or paroxysmal atrial fibrillation or recent (approximately 6 months) myocardial infarction or acute coronary syndrome.
  6. Patients with clinically significant bacterial, fungal, parasitic or viral infection which require therapy. Patients with acute bacterial infections requiring antibiotic use should delay screening/enrollment until the course of antibiotic therapy has been completed.
  7. Patients with known active hepatitis A, B, C or who are HIV-positive.
  8. Patients with inadequate bone marrow reserve at the Baseline visit as demonstrated by:

    • Absolute neutrophil count (ANC) ≤ 1000/µL.
    • Platelet count < 50,000/µL without the assistance of growth factors, thrombopoietic factors or platelet transfusions.
  9. Patients with any history of platelet counts < 50,000/µL or ANC < 500/µL except during treatment for a myeloproliferative disorder or treatment with cytotoxic therapy for any other reason.
  10. In the case of ruxolitinib pretreated patients, ruxolitinib primary resistant patients defined as:

    • No spleen reduction within the first 12 weeks after front line therapy with ruxolitinib.

    AND

    • No reduction in symptoms within the first 12 weeks after first-line treatment with ruxolitinib.

  11. In the case of ruxolitinib pretreated patients, patients discontinuing ruxolitinib due to a Grade 4 Adverse event (AE) related or suspected to be related to ruxolitinib.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01493414


  Hide Study Locations
Locations
Layout table for location information
Algeria
Novartis Investigative Site
Alger, Algeria
Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina, 1209
Novartis Investigative Site
Caba, Buenos Aires, Argentina, C1221ADC
Novartis Investigative Site
Paraná, Entre Rios, Argentina, E3100BBJ
Novartis Investigative Site
Buenos Aires, Argentina, C1114AAN
Novartis Investigative Site
Cordoba, Argentina, X5016KEH
Novartis Investigative Site
Corrientes, Argentina, W3410AVV
Austria
Novartis Investigative Site
Innsbruck, Tyrol, Austria, 6020
Novartis Investigative Site
Graz, Austria, A-8036
Novartis Investigative Site
Linz, Austria, 4010
Novartis Investigative Site
Linz, Austria, A-4010
Novartis Investigative Site
Salzburg, Austria, 5020
Novartis Investigative Site
Wien, Austria, 1140
Novartis Investigative Site
Wien, Austria, A-1090
Belgium
Novartis Investigative Site
Arlon, Luxembourg, Belgium, 1210
Novartis Investigative Site
Antwerpen, Belgium, 2060
Novartis Investigative Site
Brugge, Belgium, 8000
Novartis Investigative Site
Brussel, Belgium, 1090
Novartis Investigative Site
Bruxelles, Belgium, 1070
Novartis Investigative Site
Charleroi, Belgium, 6000
Novartis Investigative Site
Edegem, Belgium, 2650
Novartis Investigative Site
Gent, Belgium, 9000
Novartis Investigative Site
Hasselt, Belgium, 3500
Novartis Investigative Site
Kortrijk, Belgium, 8500
Novartis Investigative Site
Leuven, Belgium, 3000
Novartis Investigative Site
Liege, Belgium, 4000
Novartis Investigative Site
Roeselare, Belgium, 8800
Novartis Investigative Site
Wilrijk, Belgium, 2610
Novartis Investigative Site
Yvoir, Belgium, 5530
Brazil
Novartis Investigative Site
Goiania, GO, Brazil, 74605-050
Novartis Investigative Site
Belo Horizonte, MG, Brazil, 30130-100
Novartis Investigative Site
Curitiba, PR, Brazil, 80060-900
Novartis Investigative Site
Rio de Janeiro, RJ, Brazil, 20.211-030
Novartis Investigative Site
Porto Alegre, RS, Brazil, 90035-003
Novartis Investigative Site
Campinas, SP, Brazil, 13083-970
Novartis Investigative Site
Ribeirao Preto, SP, Brazil, 14048-900
Novartis Investigative Site
São Paulo, SP, Brazil, 01224-000
Novartis Investigative Site
São Paulo, SP, Brazil, 05651-901
Novartis Investigative Site
São Paulo, SP, Brazil, 08270-070
Canada, Alberta
Novartis Investigative Site
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
Novartis Investigative Site
Vancouver, British Columbia, Canada, V6Z1Y6
Canada, New Brunswick
Novartis Investigative Site
Moncton, New Brunswick, Canada, E1C 6Z8
Canada, Newfoundland and Labrador
Novartis Investigative Site
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
Canada, Nova Scotia
Novartis Investigative Site
Halifax, Nova Scotia, Canada, B3H 1V7
Canada, Ontario
Novartis Investigative Site
Hamilton, Ontario, Canada, L8V 5C2
Novartis Investigative Site
Ottawa, Ontario, Canada, K1H 8L6
Novartis Investigative Site
Toronto, Ontario, Canada, M5G 2M9
Novartis Investigative Site
Windsor, Ontario, Canada, N8W 2X3
Canada, Quebec
Novartis Investigative Site
Montreal, Quebec, Canada, H2W 1S6
Novartis Investigative Site
Québec, Quebec, Canada, G1J 1Z4
Canada, Saskatchewan
Novartis Investigative Site
Saskatoon, Saskatchewan, Canada, S7N 4H4
Colombia
Novartis Investigative Site
Bogota, Cundinamarca, Colombia, 111411
Novartis Investigative Site
Medellín, Colombia
Czechia
Novartis Investigative Site
Brno, Czech Republic, Czechia, 639 00
Novartis Investigative Site
Hradec Kralove, Czech Republic, Czechia, 500 05
Novartis Investigative Site
Praha 2, Czech Republic, Czechia, 128 20
Novartis Investigative Site
Olomouc, Czechia, 775 20
Germany
Novartis Investigative Site
Mannheim, Baden-Württemberg, Germany, 68305
Novartis Investigative Site
Aachen, Germany, 52074
Novartis Investigative Site
Aschaffenburg, Germany, 63739
Novartis Investigative Site
Bamberg, Germany, 96049
Novartis Investigative Site
Berlin, Germany, 13353
Novartis Investigative Site
Berlin, Germany, 14195
Novartis Investigative Site
Bochum, Germany, 44787
Novartis Investigative Site
Bonn, Germany, 53113
Novartis Investigative Site
Bonn, Germany, 53119
Novartis Investigative Site
Bottrop, Germany, 46236
Novartis Investigative Site
Bremen, Germany, 28177
Novartis Investigative Site
Chemnitz, Germany, 09113
Novartis Investigative Site
Darmstadt, Germany, 64283
Novartis Investigative Site
Dortmund, Germany, 44263
Novartis Investigative Site
Dresden, Germany, 01307
Novartis Investigative Site
Duisburg, Germany, 47166
Novartis Investigative Site
Düsseldorf, Germany, 40225
Novartis Investigative Site
Erlangen, Germany, 91054
Novartis Investigative Site
Essen, Germany, 45147
Novartis Investigative Site
Frankfurt, Oder, Germany, 15236
Novartis Investigative Site
Frankfurt, Germany, 60389
Novartis Investigative Site
Frankfurt, Germany, 60590
Novartis Investigative Site
Freiburg, Germany, 79106
Novartis Investigative Site
Friedrichshafen, Germany, 88045
Novartis Investigative Site
Goslar, Germany, 38642
Novartis Investigative Site
Greifswald, Germany, 17475
Novartis Investigative Site
Göttingen, Germany, D-37075
Novartis Investigative Site
Halle, Germany, 06110
Novartis Investigative Site
Hamburg, Germany, 20099
Novartis Investigative Site
Hamburg, Germany, 20246
Novartis Investigative Site
Hamm, Germany, 59063
Novartis Investigative Site
Hannover, Germany, 30625
Novartis Investigative Site
Hildesheim, Germany, 31135
Novartis Investigative Site
Ingolstadt, Germany, 85049
Novartis Investigative Site
Jena, Germany, 07740
Novartis Investigative Site
Kiel, Germany, D-24116
Novartis Investigative Site
Koeln, Germany, 50671
Novartis Investigative Site
Köln, Germany, 50937
Novartis Investigative Site
Leer, Germany, 26789
Novartis Investigative Site
Leipzig, Germany, 04103
Novartis Investigative Site
Magdeburg, Germany, 39120
Novartis Investigative Site
Mainz, Germany, 55131
Novartis Investigative Site
Marburg, Germany, 35037
Novartis Investigative Site
Marburg, Germany, 35039
Novartis Investigative Site
Minden, Germany, 32429
Novartis Investigative Site
Moers, Germany, 47441
Novartis Investigative Site
Muenchen, Germany, 80331
Novartis Investigative Site
Muenchen, Germany, 81241
Novartis Investigative Site
München, Germany, 81675
Novartis Investigative Site
Nuernberg, Germany, 90403
Novartis Investigative Site
Oldenburg, Germany, 26133
Novartis Investigative Site
Rostock, Germany, 18057
Novartis Investigative Site
Stuttgart, Germany, 70376
Novartis Investigative Site
Ulm, Germany, 89081
Novartis Investigative Site
Wuerzburg, Germany, 97080
Greece
Novartis Investigative Site
Athens, GR, Greece, 115 27
Novartis Investigative Site
Athens, GR, Greece, GR-106 76
Novartis Investigative Site
Athens, Greece, GR 11527
Novartis Investigative Site
Patras, Greece, 265 00
Hungary
Novartis Investigative Site
Budapest, Hungary, H-1097
Novartis Investigative Site
Debrecen, Hungary, H-4032
Novartis Investigative Site
Kaposvár, Hungary, 7400
Novartis Investigative Site
Szeged, Hungary, H-6720
Novartis Investigative Site
Szombathely, Hungary, 9700
Ireland
Novartis Investigative Site
Cork City, Cork, Ireland
Israel
Novartis Investigative Site
Afula, Israel, 1834111
Novartis Investigative Site
Haifa, Israel, 3339419
Novartis Investigative Site
Jerusalem, Israel, 9112001
Novartis Investigative Site
Petach Tikva, Israel, 49100
Novartis Investigative Site
Ramat Gan, Israel, 5266202
Novartis Investigative Site
Tel-Aviv, Israel, 6423906
Italy
Novartis Investigative Site
Alessandria, AL, Italy, 15100
Novartis Investigative Site
Ancona, AN, Italy, 60126
Novartis Investigative Site
Avellino, AV, Italy, 83100
Novartis Investigative Site
Bari, BA, Italy, 70124
Novartis Investigative Site
Bergamo, BG, Italy, 24128
Novartis Investigative Site
Bologna, BO, Italy, 40138
Novartis Investigative Site
Brescia, BS, Italy, 25123
Novartis Investigative Site
Cagliari, CA, Italy, 09100
Novartis Investigative Site
Cagliari, CA, Italy, 09126
Novartis Investigative Site
Catania, CT, Italy, 95100
Novartis Investigative Site
Catania, CT, Italy, 95124
Novartis Investigative Site
Catanzaro, CZ, Italy, 88100
Novartis Investigative Site
Cona, FE, Italy, 44100
Novartis Investigative Site
San Giovanni Rotondo, FG, Italy, 71013
Novartis Investigative Site
Firenze, FI, Italy, 50134
Novartis Investigative Site
Genova, GE, Italy, 16132
Novartis Investigative Site
Lecce, LE, Italy, 73100
Novartis Investigative Site
Monza, MB, Italy, 20900
Novartis Investigative Site
Milano, MI, Italy, 20122
Novartis Investigative Site
Milano, MI, Italy, 20133
Novartis Investigative Site
Milano, MI, Italy, 20162
Novartis Investigative Site
Modena, MO, Italy, 41100
Novartis Investigative Site
Palermo, PA, Italy, 90146
Novartis Investigative Site
Padova, PD, Italy, 35128
Novartis Investigative Site
Pescara, PE, Italy, 65124
Novartis Investigative Site
Pisa, PI, Italy, 56126
Novartis Investigative Site
Pesaro, PU, Italy, 61100
Novartis Investigative Site
Pavia, PV, Italy, 27100
Novartis Investigative Site
Rionero in Vulture, PZ, Italy, 85028
Novartis Investigative Site
Ravenna, RA, Italy, 48100
Novartis Investigative Site
Reggio Calabria, RC, Italy, 89124
Novartis Investigative Site
Reggio Emilia, RE, Italy, 42123
Novartis Investigative Site
Roma, RM, Italy, 00128
Novartis Investigative Site
Roma, RM, Italy, 00133
Novartis Investigative Site
Roma, RM, Italy, 00144
Novartis Investigative Site
Roma, RM, Italy, 00152
Novartis Investigative Site
Roma, RM, Italy, 00161
Novartis Investigative Site
Roma, RM, Italy, 00168
Novartis Investigative Site
Roma, RM, Italy, 00185
Novartis Investigative Site
Pagani, SA, Italy, 84016
Novartis Investigative Site
Siena, SI, Italy, 53100
Novartis Investigative Site
Taranto, TA, Italy, 74100
Novartis Investigative Site
Orbassano, TO, Italy, 10043
Novartis Investigative Site
Torino, TO, Italy, 10126
Novartis Investigative Site
Terni, TR, Italy, 05100
Novartis Investigative Site
Treviso, TV, Italy, 31100
Novartis Investigative Site
Udine, UD, Italy, 33100
Novartis Investigative Site
Varese, VA, Italy, 21100
Novartis Investigative Site
Venezia, VE, Italy, 30174
Novartis Investigative Site
Vicenza, VI, Italy, 36100
Novartis Investigative Site
Verona, VR, Italy, 37126
Novartis Investigative Site
Ronciglione, VT, Italy, 01100
Novartis Investigative Site
Napoli, Italy, 80131
Novartis Investigative Site
Napoli, Italy, 80132
Novartis Investigative Site
Napoli, Italy, 80136
Novartis Investigative Site
Novara, Italy, 28100
Novartis Investigative Site
Pavia, Italy, 27100
Novartis Investigative Site
Perugia, Italy, 06129
Mexico
Novartis Investigative Site
Mexico, Distrito Federal, Mexico, 06726
Novartis Investigative Site
Guadalajara, Jalisco, Mexico, 44280
Novartis Investigative Site
Monterrey, Nuevo León, Mexico, 64020
Novartis Investigative Site
Hermosillo, Sonora, Mexico, 83000
Novartis Investigative Site
Puebla, Mexico, 72000
Morocco
Novartis Investigative Site
Marrakech, Morocco
Poland
Novartis Investigative Site
Gdansk, Poland, 80-958
Novartis Investigative Site
Katowice, Poland, 40-027
Novartis Investigative Site
Krakow, Poland, 31-503
Novartis Investigative Site
Opole, Poland, 45-372
Novartis Investigative Site
Torun, Poland, 87-100
Novartis Investigative Site
Warszawa, Poland, 02-776
Portugal
Novartis Investigative Site
Coimbra, Portugal, 3000-075
Novartis Investigative Site
Faro, Portugal, 8000-386
Novartis Investigative Site
Lisboa, Portugal, 1749-035
Novartis Investigative Site
Porto, Portugal, 4099-001
Novartis Investigative Site
Vila Real, Portugal, 5000 - 508
Russian Federation
Novartis Investigative Site
Irkutsk, Russian Federation, 664079
Novartis Investigative Site
Moscow, Russian Federation, 125167
Novartis Investigative Site
Nizhnii Novgorod, Russian Federation, 603126
Novartis Investigative Site
Novosibirsk, Russian Federation, 630051
Novartis Investigative Site
Rostov-on-Don, Russian Federation, 344022
Novartis Investigative Site
St Petersburg, Russian Federation, 191024
Novartis Investigative Site
St Petersburg, Russian Federation, 197341
Saudi Arabia
Novartis Investigative Site
Jeddah, Saudi Arabia, 21423
Novartis Investigative Site
Riyadh, Saudi Arabia, 11426
Slovakia
Novartis Investigative Site
Bratislava, Slovakia, 85107
South Africa
Novartis Investigative Site
Soweto, Gauteng, South Africa, 2013
Novartis Investigative Site
Cape Town, Western Province, South Africa, 7801
Novartis Investigative Site
Johannesburg, South Africa, 2196
Novartis Investigative Site
Pretoria, South Africa, 0001
Novartis Investigative Site
Pretoria, South Africa, 0027
Spain
Novartis Investigative Site
Ferrol, A Coruna, Spain, 15405
Novartis Investigative Site
Granada, Andalucia, Spain, 18014
Novartis Investigative Site
Malaga, Andalucia, Spain, 29010
Novartis Investigative Site
Sevilla, Andalucia, Spain, 41009
Novartis Investigative Site
Sevilla, Andalucia, Spain, 41013
Novartis Investigative Site
Cadiz, Andalucía, Spain, 11009
Novartis Investigative Site
Jaen, Andalucía, Spain, 23007
Novartis Investigative Site
Oviedo, Asturias, Spain, 33006
Novartis Investigative Site
Sabadell, Barcelona, Spain, 08208
Novartis Investigative Site
Santander, Cantabria, Spain, 39008
Novartis Investigative Site
Toledo, Castilla La Mancha, Spain, 45071
Novartis Investigative Site
Burgos, Castilla Y Leon, Spain, 09005
Novartis Investigative Site
Salamanca, Castilla Y Leon, Spain, 37007
Novartis Investigative Site
Valladolid, Castilla Y Leon, Spain, 47012
Novartis Investigative Site
Badalona, Catalunya, Spain, 08916
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08003
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08036
Novartis Investigative Site
Girona, Catalunya, Spain, 17007
Novartis Investigative Site
Hospitalet de LLobregat, Catalunya, Spain, 08907
Novartis Investigative Site
Tarragona, Catalunya, Spain, 43005
Novartis Investigative Site
Alicante, Comunidad Valenciana, Spain, 03010
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46010
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46026
Novartis Investigative Site
Santiago de Compostela, Galicia, Spain, 15706
Novartis Investigative Site
Palma De Mallorca, Islas Baleares, Spain, 07120
Novartis Investigative Site
Las Palmas de Gran Canaria, Las Palmas De G.C, Spain, 35010
Novartis Investigative Site
Alcala de Henares, Madrid, Spain, 28805
Novartis Investigative Site
Majadahonda, Madrid, Spain, 28222
Novartis Investigative Site
Pozuelo de Alarcón, Madrid, Spain, 28223
Novartis Investigative Site
San Sebastian de los Reyes, Madrid, Spain, 28702
Novartis Investigative Site
El Palmar, Murcia, Spain, 30120
Novartis Investigative Site
Pamplona, Navarra, Spain, 31008
Novartis Investigative Site
Bilbao, Pais Vasco, Spain, 48013
Novartis Investigative Site
San Sebastian, Pais Vasco, Spain, 20080
Novartis Investigative Site
Logrono, Rioja, Spain, 26006
Novartis Investigative Site
La Laguna, Santa Cruz De Tenerife, Spain, 38320
Novartis Investigative Site
Baracaldo, Vizcaya, Spain, 48903
Novartis Investigative Site
Barcelona, Spain, 08041
Novartis Investigative Site
Las Palmas de Gran Canaria, Spain, 35016
Novartis Investigative Site
Madrid, Spain, 28006
Novartis Investigative Site
Madrid, Spain, 28034
Novartis Investigative Site
Madrid, Spain, 28040
Novartis Investigative Site
Madrid, Spain, 28041
Novartis Investigative Site
Madrid, Spain, 28046
Novartis Investigative Site
Zaragoza, Spain, 50009
Novartis Investigative Site
Zaragoza, Spain, 50015
Thailand
Novartis Investigative Site
Bangkok, Thailand, 10330
Novartis Investigative Site
Bangkok, Thailand, 10400
Novartis Investigative Site
Bangkok, Thailand, 10700
Novartis Investigative Site
Chiang Mai, Thailand, 50200
Tunisia
Novartis Investigative Site
Sfax, Tunisie, Tunisia, 3029
Novartis Investigative Site
Sousse, Tunisia, 4000
Novartis Investigative Site
Tunis, Tunisia, 1008
Novartis Investigative Site
Tunis, Tunisia
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  Study Documents (Full-Text)

Documents provided by Novartis ( Novartis Pharmaceuticals ):
Statistical Analysis Plan  [PDF] April 26, 2017
Study Protocol  [PDF] March 21, 2016


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01493414     History of Changes
Other Study ID Numbers: CINC424A2401
2010-024473-39 ( EudraCT Number )
First Posted: December 16, 2011    Key Record Dates
Results First Posted: April 26, 2019
Last Update Posted: April 26, 2019
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Myelofibrosis
Primary myelofibrosis
PMF
Post polycythemia myelofibrosis
PPV MF
Post-essential thrombocythemia myelofibrosis
PET-MF
INC424
Ruxolitinib
Additional relevant MeSH terms:
Layout table for MeSH terms
Primary Myelofibrosis
Polycythemia
Thrombocytosis
Thrombocythemia, Essential
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Blood Platelet Disorders
Blood Coagulation Disorders
Hemorrhagic Disorders